0000930413-17-003670.txt : 20171030
0000930413-17-003670.hdr.sgml : 20171030
20171030211819
ACCESSION NUMBER: 0000930413-17-003670
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171027
FILED AS OF DATE: 20171030
DATE AS OF CHANGE: 20171030
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'Brien James Michael
CENTRAL INDEX KEY: 0001632111
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09974
FILM NUMBER: 171163855
MAIL ADDRESS:
STREET 1: C/O ENZO BIOCHEM INC.
STREET 2: 527 MADISON AVE.
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENZO BIOCHEM INC
CENTRAL INDEX KEY: 0000316253
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 132866202
STATE OF INCORPORATION: NY
FISCAL YEAR END: 0731
BUSINESS ADDRESS:
STREET 1: 60 EXECUTIVE BLVD
CITY: FARMINGDALE
STATE: NY
ZIP: 11735
BUSINESS PHONE: 5167555500
MAIL ADDRESS:
STREET 1: ENZO BIOCHEM INC
STREET 2: 60 EXECUTIVE BLVD
CITY: FARMINGDALE
STATE: NY
ZIP: 11735
4
1
c89632_4.xml
X0306
4
2017-10-27
0
0000316253
ENZO BIOCHEM INC
ENZ
0001632111
O'Brien James Michael
C/O ENZO BIOCHEM INC.
527 MADISON AVE.
NEW YORK
NY
10022
0
1
0
0
EVP of Finance
Common Stock
2017-10-27
4
M
0
6699
2.75
A
34886
D
Common Stock
2017-10-27
4
M
0
7500
3.40
A
42386
D
Common Stock
2017-10-27
4
M
0
8667
4.35
A
51053
D
Common Stock
2017-10-27
4
S
0
6699
10.28
D
44354
D
Common Stock
2017-10-27
4
S
0
7500
10.28
D
36854
D
Common Stock
2017-10-27
4
S
0
8667
10.28
D
28187
D
Stock Option (to acquire common stock)
2.75
2017-10-27
4
M
0
6699
2.75
D
2015-02-04
2019-02-03
Common Stock
6699
68501
D
Stock Option (to acquire common stock)
3.40
2017-10-27
4
M
0
7500
3.40
D
2016-01-22
2020-01-21
Common Stock
7500
61001
D
Stock Option (to acquire common stock)
4.35
2017-10-27
4
M
0
8667
4.35
D
2017-03-15
2021-03-15
Common Stock
8667
52334
D
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.40, inclusive. The reporting person undertakes to provide to the Issuer, any
security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ James Michael O'Brien
2017-10-30